Celgosivir hydrochloride is primarily used in the research and development of antiviral therapies. It has shown potential in inhibiting the replication of certain viruses, particularly those in the flavivirus family, such as dengue and hepatitis C. The compound acts as an alpha-glucosidase inhibitor, disrupting the glycosylation process of viral proteins, which is crucial for viral maturation and infectivity. This mechanism makes it a candidate for antiviral drug development. Additionally, it has been explored for its potential in cancer research, where glycosylation inhibitors are studied for their ability to alter tumor cell behavior and enhance the efficacy of other treatments. Its application remains largely in the experimental and preclinical stages, with ongoing studies to evaluate its safety and effectiveness.